Galectin-3: clinical utility and prognostic value in patients with heart failure

Research Reports in Clinical Cardiology. 2013;2013(default):13-22

 

Journal Homepage

Journal Title: Research Reports in Clinical Cardiology

ISSN: 1179-8475 (Online)

Publisher: Dove Medical Press

LCC Subject Category: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS

Kramer F

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks

 

Abstract | Full Text

Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification